Liver-disease is an extremely serious problem in Mongolia; it was for this reason President Kh.Battulga met representatives of US-based Eiger BioPharmaceuticals Inc. which has been providing effective solutions in the country. Among the group meeting the head-of-state were David A. Cory, President and CEO, Ingrid Choong, Vice President of Investor Relations and Corporate Development, and John Ferraro, Vice President of Clinical Operations.

The company has been working with Mongolian doctors, especially the Onom Foundation, which is committed to liver diseases, for the last 11 years. The representatives spoke about this cooperation with President Kh.Battulga, while exchanging views on the necessity to introduce the treatment of the Hepatitis Delta Virus (HDV) infection; other matters relating to liver disease in Mongolia were also discussed.

Eiger BioPharmaceuticals is currently implementing Phase 3 of its lead programme which focuses on developing a treatment for the HDV infection.

Mongolia launched the “Whole-Liver Mongolia” national programme in May 2017, and over 350,000 people aged 40-65 being tested for hepatitis B and C for free in the first phase; over 70 percent of those diagnosed with hepatitis received treatment.